SCHEMBL2341504

SCHEMBL2341504

COc1cc2c(cc1OC(F)F)C(c1ccc(N3CCOCC3)nc1)=NC1CCC(OC(C)=O)CC21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.43
PDE4D Q08499 2/20 0.40
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
ERN1 O75460 1/20 0.39
MAP4K1 Q92918 1/20 0.37
TLR8 Q9NR97 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
SIK1 P57059 2/20 0.36
SIK2 Q9H0K1 2/20 0.36
SIK3 Q9Y2K2 2/20 0.36
ZAP70 P43403 1/20 0.35
MTOR P42345 1/20 0.35
GAK O14976 1/20 0.34
FGFR1 P11362 1/20 0.34
FGFR4 P22455 1/20 0.34
TDO2 P48775 1/20 0.34
CNR2 P34972 2/20 0.33
MAP3K12 Q12852 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2347234 0.92 PDE4D (0.42) PDE10APDE4DPDE4APDE4BPDE4C
SCHEMBL2344810 0.91 PDE4D (0.48) PDE10APDE4DPDE4APDE4BPDE4C
SCHEMBL2264546 0.89 PDE10A (0.45) PDE10APDE4DPDE4APDE4BPDE4C
SCHEMBL2268015 0.83 PDE10A (0.49) PDE10APDE4DPDE4APDE4BPDE4C
SCHEMBL2263916 0.83 PDE4D (0.49) PDE10APDE4DPDE4APDE4BPDE4C
SCHEMBL3470263 0.82 PDE4D (0.46) PDE4DPDE4APDE4BPDE4C
SCHEMBL2343649 0.81 PDE4D (0.38) PDE10APDE4DPDE4APDE4BPDE4C
SCHEMBL2346489 0.81 PDE4D (0.39) PDE4DPDE4APDE4BPDE4C
SCHEMBL2345712 0.81 PDE4D (0.39) PDE4DPDE4APDE4BPDE4C
SCHEMBL2263482 0.81 PDE4A (0.47) PDE10APDE4DPDE4APDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257169-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2011-10-20 US disclosed
US-20110257221-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS NYCOMED GMBH (DE) 2011-10-20 US disclosed
US-8003798-B2 Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors NYCOMED GMBH (DE) 2011-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257221-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C PDE10A 14/4885PDE4D 4/4885PDE4A 1/4885
US-20110257169-A1 NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS PDE4A, PDE4B, PDE4C PDE10A 14/4885PDE4D 4/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.